& Djavanroodi, F
Retevmo is specifically indicated for advanced or metastatic medullary thyroid cancer with a RET mutation, advanced or metastatic thyroid cancer with a RET gene fusion untreatable with radioactive iodine therapy, and locally advanced or metastatic solid tumors with a RET gene fusion that have progressed after prior systemic treatment or have no treatment options, according to the publication
doi: 10.3390/ijms22105074 60
Ingredients: Petrolatum, Hydrogenated Polyisobutene, Polyisobutene, Phytosteryl/Isostearyl/Cetyl/Stearyl/Behenyl Dimer Dilinoleate, Butyrospermum Parkii (Shea) Butter, Diisostearyl Malate, Ethylene/Propylene/Styrene Copolymer, Sorbitan Sesquioleate, Microcrystalline Wax, Vanillyl Butyl Ether, Butylene/Ethylene/Styrene Copolymer, Ethylhexylglycerin, Water, Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate, Butylene Glycol, Melia Azadirachta Leaf Extract, Melia Azadirachta Flower Extract, Coccinia Indica Fruit Extract, Amber Powder, Mentha Piperita (Peppermint) Leaf Extract, Solanum Melongena (Eggplant) Fruit Extract, Ocimum Sanctum Leaf Extract, Curcuma Longa (Turmeric) Root Extract, Corallina Officinalis Extract, Moringa Oleifera Seed Oil, Magnesium Ascorbyl Phosphate, Citric Acid, Betaine Salicylate, Anemarrhena Asphodeloides Root Extract
